Immunomodulatory Agents for Multiple Myeloma
| Authors | |
|---|---|
| Year of publication | 2022 |
| Type | Article in Periodical (without peer review) |
| MU Faculty or unit | |
| Citation | |
| Description | The treatment of multiple myeloma (MM) has undergone a significant paradigm shift in the last 20 years, from conventional chemotherapy to more tumor-specific treatments, based on the interference with pathogenesis of the malignant clone as well as the bone microenvironment. Indeed, the introduction of novel drugs with “biological mechanisms of action” into MM treatment has established a worldwide trend towards chemotherapy-free regimens with lower toxicity (or significantly different toxic profiles) and targeted mechanisms of action. Immunomodulatory drugs (IMiDs) represent the cornerstone of the evolution of novel therapy in MM. |